Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Programmed Death-ligand 1 (PD-L1)
90%
Mantle Cell Lymphoma
70%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
58%
Ribonuclease
58%
Tumor Immunity
47%
Epstein-Barr Virus
40%
Hepatocellular Carcinoma
26%
T Cell Activation
24%
Protein-protein Interaction
24%
Cyclin-dependent Kinase 9 (CDK9)
23%
Bruton's Tyrosine Kinase Inhibitors (BTKi)
22%
Immunosuppression
22%
Nuclear Transport
21%
Glycosylation
21%
Receptor Tyrosine Kinase
20%
Cancer Cells
20%
Phosphorylation
20%
Putative Drug Targets
20%
Programmed Cell Death Protein 1 (PD-1)
19%
EGF Receptor
18%
Chimeric Antigen Receptor T Cells (CAR-T)
18%
Membrane Receptors
18%
Breast Tumor
18%
Pirtobrutinib
18%
Chemotherapy Resistance
18%
Triple-negative Breast Cancer Cells
18%
Triple-negative Breast Cancer
17%
Anti-programmed Cell Death Protein 1 (anti-PD-1)
17%
Ribonuclease 7
17%
Ephrin Receptor A10
17%
Apoptosis
17%
Methylation
17%
Signaling Complex
17%
Heat Shock Protein 90 (Hsp90)
17%
ROS1
17%
Transactivator
17%
Multiparametric Analysis
17%
PARP Inhibitors (PARPi)
17%
N-linked Glycosylation
17%
RNASE1
17%
Advanced Basal Cell Carcinoma
17%
Tumor Growth
17%
Breast Cancer
17%
Tumor Cells
16%
Lytic Cycle
16%
Interaction Ratio
14%
Anti-PD-1/PD-L1 Therapy
14%
Anaplastic Lymphoma Kinase
13%
Therapeutic Efficacy
13%
Therapeutic Target
13%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Ribonuclease
63%
Cancer Cell
30%
Carcinogenesis
28%
T Cell
28%
PD-L1
27%
Nuclear Transport
20%
Phosphotransferase
20%
Kinase
20%
Tyrosine Kinase Inhibitor
19%
Bruton Tyrosine Kinase
19%
Receptor Tyrosine Kinase
19%
Chimeric Antigen Receptor
19%
Tumor Progression
18%
RNA
18%
Signal Transduction
18%
Methylation
17%
Protein Characterization
17%
P53
17%
ROS1
17%
phosphorylation
16%
Anaplastic Lymphoma Kinase
13%
Mesenchymal-Epithelial Transition
13%
Ibrutinib
12%
Immunosurveillance
12%
Nuclear Membrane
12%
Nuclear Pore
12%
Protein Interaction
12%
Mouse Model
12%
Monoclonal Antibody
11%
Ribonuclease A
11%
ErbB
10%
Drive
10%
Reprogramming
10%
DNA Synthesis
10%
Chromatin
10%
Cell Proliferation
10%
Angiogenin
10%
Glycosylation
9%
Transcription
9%
Sec61
9%
Genetics
9%
N-Linked Glycosylation
8%
Glycogen Synthase Kinase 3
8%
Epidermal Growth Factor
8%
Deglycosylation
8%
Cetuximab
8%
Translocon
8%
Transport at the Cellular Level
8%
Tumor Initiation
8%
Immunology and Microbiology
Programmed Death 1 Ligand 1
52%
Epstein Barr Virus
39%
Programmed Death-Ligand 1
37%
Cancer Cell
36%
Glycosylation
34%
Immunotherapy
29%
T Cell
25%
Immunosuppression
21%
Epidermal Growth Factor
19%
Mouse Model
17%
Virus Reactivation
15%
Lytic Cycle
15%
Immunosurveillance
14%
Phosphotransferase
13%
Kinase
13%
Carcinoma Cell
13%
Cell Activity
12%
Monoclonal Antibody
12%
Immune Escape
12%
Syngenic
11%
phosphorylation
11%
Tumor Cell
11%
Binding Affinity
10%
In Vitro
10%
Cetuximab
10%
Adaptive Immune System
10%
Cell Lysate
9%
Ribonucleic Acid
9%
Programmed Death 1 Receptor
9%
Protein Characterization
8%
Anaplastic Lymphoma Kinase
8%
Immune Evasion
8%
Susceptibility
8%
Arginine
8%
Immediate Early Protein BZLF1
8%
T Cell Activation
8%
Endoplasmic Reticulum Associated Degradation
8%
Therapeutic Antibodies
8%
Lymphoma Cell
8%
Aerobic Glycolysis
8%
Major Histocompatibility Complex
8%
Interleukin 6
8%
RNAI
8%
Citric Acid Cycle
8%
Chimeric Antigen Receptor T-Cell
8%
Histone
8%
Genetic Transcription
8%
Methylation
8%
Receptor Occupancy
8%
Epstein-Barr Virus Latent Membrane Protein 1
8%
